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Summary 
 
Parkinson’s Disease is a neurodegenerative 
disease that is pathologically characterized by 
abnormal α-synuclein protein aggregation, 
dopamine depletion in nigrostriatal neurons, and 
the subsequent death of these neurons. Oxidative 
stress has been widely implicated as a cause for 
neurodegenerative diseases, especially Parkinson’s 
Disease (PD). The mechanisms by which oxidative 
stress occurs in PD neurons and causes cell death 
remain obscure. Recent research has revealed 
several mechanisms by which α-synuclein and 
oxidative stress may induce cell death in PD, 
providing potential targets for therapies. The roles 
of α-synuclein, PD-inducing drugs, and DJ-1 as well 
as their involvement in oxidative stress production 
and apoptosis are reviewed. 
 
Introduction 
 
Parkinson’s disease (PD) is a progressive 
neurodegenerative disorder that afflicts one million 
people in the U.S., and four million people worldwide. It 
is characterized by resting tremors, postural instability, 
and bradykinesia (Olanow and Tatton, 1999)—all 
symptoms which result from the death of dopamine 
producing neurons in the substantia nigra pars 
compacta. Although five percent of PD cases result 
from genetic mutations in one of several key genes, 
ninety-five percent of PD cases are sporadic. This 
review explores oxidative stress as a contributor to 
sporadic PD.  
Reactive oxygen species (ROS), such as 
superoxide, hydrogen peroxide, and the hydroxyl 
radical, are reactive molecules that cause cellular 
stress. Mitochondria can generate ROS within the cell 
during normal metabolic reactions, and these free 
radicals can significantly damage other cellular 
structures, including lipid membranes, proteins in 
important cellular machinery, and DNA. In PD patients, 
increased lipid peroxidation (Dexter et al., 1986), protein 
carbonylation (Alam et al., 1997a), and oxidation of 
DNA (Alam et al., 1997b) have all been detected in the 
substantia nigra, implying the occurrence of oxidative 
stress within these neurons. The inhibition of complex I 
of the mitochondria has been shown to generate ROS, 
which can damage the electron-transport chain and 
lead to further production of ROS (Dauer and 
Przedborski, 2003). Several studies have confirmed the 
deficiency of complex I in the brains of PD patients 
(Schapira et al., 1989; Mizuno et al., 1989; Parker et al., 
1989), and the death of dopaminergic neurons has 
been shown to increase when complex I of the 
mitchondria is deficient (Kweon et al., 2004). These  
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markers of oxidative stress have led to research aiming 
to discover the mechanisms behind oxidative stress 
and cell death in PD. 
 
Modeling PD with drugs 
 
Several molecular species and drugs are thought to 
lead to the onset of PD and have been used to 
successfully produce Parkinsonism in model 
organisms.  Dopamine, itself, is thought to be the single 
most important species that contributes to oxidative 
stress conditions in the brains of PD patients. While this 
neurotransmitter is the molecular species that enables 
neuronal activity, its oxidized metabolites can act as 
endogenous neurotoxins within these neurons 
(Hastings and Zigmond, 1997).  Dopamine can undergo 
auto-oxidation and form reactive dopamine quinones or 
6-hydroxydopamine (6-OHDA), which can generate the 
deleterious hydroxyl radical and hydrogen peroxide 
species (Heikkila and Cohen, 1973; Slivka and Cohen, 
1985). 6-OHDA induces nirgostriatal neuronal death in 
rats (Mendez and Finn, 1975; Javoy et al., 1976) and 
human neuroblastoma (Simantov et al., 1996). Because 
dopamine depletion is a common pathology of PD, 
therapies, such as L-dopa, have aimed to replace 
dopamine within surviving neurons in order to restore 
their function, thus reducing the symptoms of PD. 
Although L-dopa, which was first used in the 1960s, is 
effective in restoring nigrostriatal function, its long term 
effects are now under investigation because L-dopa is 
converted to dopamine in the patient, and which can 
then undergo auto-oxidation and form toxic species.  
The connection between oxidative stress and 
PD has also been strengthened by the effects of 
several drugs on nigrostriatal dopaminergic neurons. 
The drug MPTP has been shown to cause extensive 
dopaminergic neuronal death in the substantia nigra, 
leading to Parkinson’s Disease. This drug has been 
used to model PD in animals and has revealed findings 
such as parkinsonism in non-human primates (Burns et 
al., 1983) as well as the loss of movement in mice 
(Sundstrom et al., 1990), rats (Sahgal et al., 1984), and 
zebrafish (Bretaud et al., 2004). When this drug is 
oxidized to its metabolite, MPP+, it inhibits 
mitochondrial respiration by blocking the flow of 
electrons in complex I (Ramsay et al., 1991), leading to 
increased levels of ROS (Singer et al., 1987). Because 
MPTP causes oxidative stress and PD, examining its 
effects in model organisms may elucidate mechanisms 
that show oxidative stress is a precursor or result of PD. 
Rotenone is another complex I inhibitor that 
has been used to model PD in rats (Betarbet et al., 
2000) and Drosophila (Coulom et al., 2004). It has been 
shown to induce apoptosis at low concentrations in 
neuronal PC-12 cells (Hartley et al., 1994) and to 
increase oxidative stress conditions, increase α-
synuclein accumulation, and induce apoptosis in human 
neuroblastoma (Sherer et al., 2002). Another molecule, 
paraquat, is an oxidative herbicide that has also been 
used to model PD. It was first shown to cause 
neurodegeneration in rats (Corasaniti et al., 1992) and 
has since been shown to cause apoptosis in PC-12 
cells (Li and Sun, 1999) and dopaminergic cell loss in 
mice (Brooks et al., 1999). The mechanisms by which 
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6-OHDA, MPTP, rotenone, and paraquat cause cell 
death are only partially understood. Both MPP+ and 
rotenone bind to either the same or adjacent sites in 
complex I of the mitochondria to inhibit mitochondrial 
respiration (Ramsay et al., 1999; Krueger et al., 1990), 
indicating that they induce neuronal death via similar 
mechanisms. In addition, MPP+ is transported into cells 
via the dopamine transporter (DAT), accounting for its 
selectivity in targeting dopaminergic neurons (Kitayama 
et al., 1992; Kitayama et al., 1993). On the other hand, 
one study has shown that, while MPP+ causes cell 
death via inhibition of mitochondrial complex I, 6-OHDA 
apoptosis occurs independent of mitochondrial 
impairment (Wu et al., 1996).  
Most recent studies have shown a 
relationship between 6-OHDA neurotoxicity and 
cyclooxygenase (COX) activity (Carrasco et al., 2005). 
COX is an enzymatic mediator of inflammation 
(McDaniel et al., 1996) that has been found at 
increased levels in the dopaminergic neurons of PD 
patients (Knott et al., 2000). Regular use of non-
steroidal anti-inflammatory drugs, such as ibuprofen, 
has been shown to reduce the risk of PD (Casper et al., 
2000; Chen et al., 2005). A recent study has shown that 
ibuprofen, a non-selective inhibitor of COX activity, 
attenuated the death of embryonic rat mesencephalic 
neurons by 6-OHDA, but not MPP+ (Carrasco et al., 
2005). Furthermore, a specific inhibitor of COX-2 was 
shown to decrease 6-OHDA toxicity, while no 
correlation was shown for COX-1. This study further 
supports that, in addition to the ability to generate ROS, 
6-OHDA could be involved in a toxic mechanism that is 
seemingly independent of oxidative stress conditions.  
While rotenone is a well-studied complex I 
inhibitor, it has recently been shown to be involved in 
an apoptotic pathway. Bcl-2 is a protein that prevents 
apoptosis induced by the fas cell death receptor 
(Jaattela et al., 1995), and BAD is a protein that blocks 
the activity of Bcl-2, thereby causing cell death (Yang et 
al., 1995). Rotenone has been shown to 
dephosphorylate the BAD protein in human 
dopaminergic SH-SY5Y cells, an event that allows BAD 
to block Bcl-2 (Watabe and Nakaki, 2004). Both 
rotenone’s involvement in the Bcl-2 pathway and 6-
OHDA’s involvement in COX activity present evidence 
that these PD-inducing agents may cause neuronal 
toxicity via apoptotic pathways not only by contributing 
to oxidative stress conditions. This suggests that these 
species may have dual roles in causing PD. Further 
studies may someday link these toxic species’ 
involvement in apoptosis to oxidative stress, as 
mitochondria are primary producers of ROS and are 
involved in the initiation of apoptotic pathways. 
Fortunately, cells are equipped with machinery to 
combat the ROS that can lead to untimely cell death. 
 
Oxidative stress enzymes and PD 
 
Over the course of evolution, cells have constructed 
enzymatic machinery to combat oxidative stress. For 
example, superoxide dismutase (SOD) is an enzyme 
that catalyzes the reaction of the superoxide radical 
(O2·-) to hydrogen peroxide and molecular oxygen (O2). 
This enzyme is a protein complex that can have various 
types of metal ion content (mangansese, copper-zinc, 
and iron). Manganese superoxide dismutase (SOD2) is 
found in the matrix of mitochondria (Slot et al., 1986), 
which is the sight of oxidative phosphorylation. 
Theoretically, an antioxidant defense system would be 
required in this area of the cell since the normal 
process of oxidative phosphorylation can give rise to 
superoxide radicals. Copper-zinc superoxide dismutase 
(SOD1) is located in the cytosol and comprises a rather 
large fraction of a cell’s total protein (10µM in yeast) 
(Rae et al., 1999), while iron superoxide dismutase 
(SOD3) is extracellular. Catalase and glutathione are 
two other antioxidant enzymes that catalyze the 
reaction of hydrogen peroxide to molecular oxygen and 
water, thereby reducing a major source of oxidative 
stress. All of these enzymes have been shown to confer 
protection of neurons against oxidative stress. 
SODs, specifically, have been examined in 
many studies of neurodegeneration. Perhaps the best 
known example is the role of SOD1 in amyotrophic 
lateral sclerosis (ALS), also known as Lou Gherig’s 
disease. Twenty percent of familial ALS cases are 
caused by mutations in the SOD1 gene, which causes 
abnormal SOD1 protein aggregation (Rosen et al., 
1993). SOD1 has also been shown to alleviate Aβ 
toxicity by scavenging free radicals generated by the 
abberant Alzheimer’s protein (Bowling and Beal, 1995). 
Moreover, both SOD1 and SOD2 are upregulated in 
neuronal regions containing neurofibrillary tangles and 
plaques in AD patients (Delacourte et al., 1988).  
Many studies have also examined the roles 
of SODs in the protection against oxidative stress in 
PD. Because SOD2 is the major free radical scavenger 
in mitochondria, the SOD2 gene has been closely 
examined in many studies in an attempt to find a 
possible link between the gene and genetic PD cases; 
however, no such correlation has been identified (Jones 
et al., 1998; Farin et al., 2001). But because SOD2 is 
an essential enzyme against mitochondrial oxidative 
stress, SOD2 knockouts have been used as a model of 
endogenous oxidative stress (Hinerfeld et al., 2004). 
Moreover, MPTP-treated mice are more susceptible to 
striatal lesions and dopamine depletion when SOD2 is 
partially deficient (Andreassen et al., 2001). 
Interestingly, SOD2 was also identified as a gene that 
protected against α-synuclein toxicity to yeast cells 
expressing the α-synuclein protein (Willingham et al., 
2003). By delineating the activity of oxidative stress 
enzymes in protecting model organisms from cell death 
under PD-inducing conditions, the role of oxidative 
stress in PD is strengthened. In a genetic cause of PD, 
this relationship between cell death and oxidative stress 
becomes more apparent. 
 
 
Genetic Evidence of Oxidative Stress in PD 
 
A familial mutation and the deletion of the DJ-1 gene 
have been shown to induce autosomal, recessive, 
early-onset PD (Bonifati et al., 2003). DJ-1 is an 
antioxidant protein that eliminates hydrogen peroxide 
by undergoing auto-oxidation (Taira et al., 2004). 
Neuroblastoma cells with DJ-1 knockdown by siRNA 
are susceptible to death by 6-OHDA, hydrogen 
peroxide, and MPP+, all Parkinson’s inducing agents 
(Taira et al., 2004). Moreover, DJ-1 overexpression 
protects cultured primary dopamine neurons and rat 
dopaminergic neurons from hydrogen peroxide and 6-
OHDA induced death by the upregulation of glutathione 
levels (Zhou and Freed, 2005). Another study has 
shown that the knockdown of DJ-1 or the expression of 
mutant DJ-1 in a mouse cell line resulted in the 
downregulation of extracellular iron-SOD expression 
(Nishinaga et al., 2005), suggesting that normal DJ-1 
can regulate gene expression to protect against cell 
death. The discovery of this gene’s connection to PD 
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Figure 1: α-synuclein, oxidative stress, and DJ-1 involvement in the JNK pathway may explain cell death in PD. 
Several studies support the involvement of the JNK apoptotic pathway in the cell death observed in PD. α-Synuclein is can bind to the JNK-
interacting protein (JIP) to inactivate JNK and prevent apoptosis. DJ-1 can bind to Daxx and prevent its association with the fas death 
receptor, inactivating the JNK pathway and also preventing apoptosis. Rotenone can dephosphorylate BAD, which blocks Bcl-2 from 
inactivating the JNK pathway, thereby causing apoptosis. 
 
presents significant genetic evidence that implicates 
oxidative stress as a cause of PD. 
 DJ-1 has many other functions in addition to 
its ability to quench ROS. A recent study has revealed 
that DJ-1 binds to the Daxx protein (Junn et al., 2005), 
a protein that binds to a fas death receptor (Yang et al., 
1997) and activates the JNK (c-Jun N-terminal kinase) 
apoptotic pathway.  Junn and colleagues discovered 
that when DJ-1 binds to Daxx, it sequesters the protein 
into the nucleus and prevents it from gaining access to 
the cytoplasm and from inducing apoptosis at the fas 
death receptor. Interestingly, Daxx upregulation occurs 
in cells that are treated with the oxidant hydrogen 
peroxide (Kim et al., 2005), linking oxidative stress to 
the activation of this apoptotic pathway. These studies 
together show that DJ-1 is involved in inactivating the 
apoptotic JNK pathway that is activated by oxidative 
stress, indicating its indirect role in guarding against 
oxidative stress-induced cell death (Figure 1).  
 
α-Synuclein and Oxidative Stress 
 
The common pathological hallmark among 
most cases of PD is the accumulation of misfolded α-
synuclein protein into aggregates called Lewy Bodies 
(Spillantini et al., 1997). A connection between a-
synuclein misfolding and oxidative stress has yet to be 
fully established. α-Synuclein has been shown to bind  
 
phospholipids in several in vitro and in vivo studies 
(Davidson et al., 1998; Sharon et al., 2001; Eliezer et 
al., 2001; Outeiro and Lindquist, 2003), and lipid 
peroxidation has been observed in dopaminergic 
neurons within the brains of PD patients. If lipid content 
is damaged within dopaminergic neurons, α-synuclein 
may be unable to bind to the membrane and will 
accumulate within the cytoplasm (Figure 2), accounting 
for the formation of Lewy bodies. 
An emerging theory of α-synuclein toxicity 
conversely proposes that toxic events occur with 
increased binding of α-synuclein protofibrils to the lipid 
membrane (Volles et al., 2001). This study shows that 
in contrast to monomeric and oligomeric forms of α-
synuclein, protofibrillar forms bind more tightly to 
vesicles, permeating and destroying them. This 
provides evidence that those protofibrillar forms of α-
synuclein may be the toxic species in neurons in that 
they destroy lipid membranes. Therefore, it is also a 
possibility that oxidative damage that increases α-
synuclein binding to lipid membranes can lead to toxic 
events in neurons (Figure 2). 
 α-Synuclein has been more concretely linked 
to oxidative stress with its involvement in the JNK 
pathway previously discussed. A study by Hashimoto 
and colleagues revealed that hydrogen peroxide 
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treatment resulted in the activation of the JNK pathway and death in a neuronal cell line. α-Synuclein 
 
 
Figure 2: Oxidative stress can contribute to α-synuclein dysfunction and cell death in PD.  
ROS can damage α-synuclein’s lipid binding ability and contribute to the formation of α-synuclein aggregates. ROS can also damage lipid 
membranes and prevent or promote α-synuclein binding, both events that are hypothesized to cause cell death. 
 
transfection, however, protected against this cell death, 
and JNK was inactivated due to increased expression 
of JNK-interacting protein (JIP). Moreover, α-synuclein 
was shown to co-localize with JIP. This proposes a 
protective role of α-synuclein against oxidative stress 
due to its ability to inactivate the JNK pathway via 
upregulation of JIP (Hashimoto et al., 2002). The 
protective activity of the α-synuclein may decrease if 
the protein is mutated, misfolded, or aggregated, and 
therefore unable to interact with JIP (Figure 1). Further 
studies involving oxidative stress conditions and the 
JNK pathway may bolster the connection between 
pathological forms of α-synuclein and oxidative stress.  
The formation of Lewy bodies within surviving 
nigrostriatal neurons of PD patients (Spillantini et al., 
1997) has led to two theories regarding α-synuclein 
toxicity: aggregates are precursors to cytotoxic events 
in these neurons (Goedert, 1999), or aggregates are 
cytoprotective against smaller toxic forms of misfolded 
α-synuclein (McNaught et al., 2002). A study examining 
dopamine’s interaction with α-synuclein provides 
evidence for the latter. This study revealed that 
dopamine quinones inhibited the fibrillization of α-
synuclein by reacting with the protein’s amino groups to 
form toxic, oligomeric, cross-linked, dopamine-quinone 
adducts (Li et al., 2005). Because oxidative stress 
conditions are conducive to the formation of dopamine 
quinones, this study creates a strong connection 
between dopaminergic neuronal death, α-synuclein, 
and oxidative stress.  
   
 
The function of α-synuclein has also been implicated in 
dopamine transport. Dopamine transporter (DAT) 
facilitates the reuptake of dopamine from the synaptic 
cleft back into the presynpatic neuron (Reith et al., 
1997). α-Synuclein has been shown to bind to DAT and 
assist it in clustering within the membrane to accelerate 
dopamine uptake (Lee et al., 2001). Damaged or 
aggregated α-synuclein may lead to the accumulation 
of dopamine and its subsequent oxidation into harmful 
metabolites, thus increasing oxidative stress. The role 
of α-synuclein in the JNK pathway, lipid binding, and 
dopamine transport all provide hypotheses for its 
involvement with oxidative stress conditions that may 
cause the neuronal degeneration seen in PD.  
 
Conclusion 
 
Although a great deal of progress has been 
made in delineating the mechanisms by which neuronal 
degeneration occurs in PD, there are still many gaps in 
knowledge that plague the field. Oxidative stress is 
undoubtedly a key player in neuronal degeneration in 
PD, but targeting the pathways by which it induces cell 
death cannot be considered until the mechanisms are 
fully understood.  
In reviewing studies that focus on oxidative 
stress and PD, it is apparent that α-synuclein, oxidative 
stress, and apoptosis are all related by complex 
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mechanisms that may or may not be linked. Examining 
the effects of PD-inducing agents reveals new findings  
that supports mechanisms by which oxidative stress is 
involved in the activation of specific apoptotic pathways. 
The JNK pathway is seemingly important as DJ-1, 
rotenone, and α-synuclein can all be implicated in the 
activation or inactivation of this pathway, which can 
lead to or prevent apoptosis (Figure 1).  
α-Synuclein, itself, seems to be involved in 
several cellular process due to its lipid binding abilities. 
This study has mentioned two such abilities: its 
association with JIP and its regulation of dopamine 
transport. Because α-synuclein may have several 
functions, it may also be responsible for a great deal of 
cellular dysfunction when damaged (Figures 1 & 2). 
Whether oxidative stress is a cause or effect of α-
synuclein aggregation is a major question that remains 
in the field and must be answered before any therapy 
can target either of these phenomena.  
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